The acquisition of Paratek Pharmaceuticals by Gurnet Point Capital and Novo Holdings at $3/share, including an upfront payment of $2.15/share, is a significant event for the company. The total transaction value of up to ~$462 million indicates a positive impact on the stock price in the short term, as it represents a premium to the current market price.